IQWiG Pans Gilead’s Stribild For HIV On Missing Data, Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s reimbursement watchdog IQWiG has panned Gilead’s HIV combination drug Stribild, saying it is inferior to existing therapies.